HHS Plans New FDA Leadership Roles to Oversee AI and Drug Regulation

Agency insiders suggest these appointments reflect a push by the Trump administration to exert tighter control over the FDA’s regulatory agenda. While no formal announcement has been made, Jared Seehafer, a life sciences software veteran and current FDA advisor, has emerged as the primary candidate for the technology-focused role. This position would manage both the agency’s internal adoption of generative AI tools and the external evaluation of AI-enabled medical devices.

Simultaneously, the administration intends to create a deputy commissioner for drugs. Both new appointees would report to Heidi Overton, the nominee for FDA commissioner currently awaiting Senate confirmation. The agency has endured a period of significant volatility, marked by leadership turnover and public friction over controversial drug approval decisions, including high-profile regulatory battles with firms like Replimune and UniQure. These structural changes arrive as the FDA struggles to balance internal staffing constraints with the urgent need to modernize its approach to digital health and drug safety.